Skip to content

CorMedix CRMD Contingent Consideration, short-term

Contingent Consideration, short-term at other companies

Federal Signal logo
Federal SignalFSS
$4.1M
XOMA Corporation logo
XOMA CorporationXOMA
$0
N-able logo
N-ableNABL
$10.25M-30.5%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$15.79M-10.1%
Provident Financial Services logo
Provident Financial ServicesPFS
$560K+28.4%
RingCentral logo
RingCentralRNG
$1.9M

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept crmd:ContingentConsiderationShortterm.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's contingent consideration, short-term.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's contingent consideration, short-term?
CorMedix (CRMD) reported contingent consideration, short-term of $3.18M in Q1 2026.
What does contingent consideration, short-term mean?
This represents the estimated fair value of potential future payments to sellers in an acquisition, expected to be settled within one year. It arises from earn-out provisions or performance-based milestones tied to the acquired business. This metric is critical for assessing near-term cash outflow obligations and the financial impact of past M&A activity.